U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Renal Cell Carcinoma

MedGen UID:
1714249
•Concept ID:
C5237422
•
Neoplastic Process

Definition

Renal cell carcinoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Renal Cell Carcinoma

Professional guidelines

PubMed

Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results.
Nathan P, Venugopal B, Ali J, Allison J, Ceruso M, Charnley N, Griffiths R, Michael A, Moore K, Perrot V, Prendergast Á, Sharma A, Szabados B, Larkin J
Clin Genitourin Cancer 2024 Oct;22(5):102141. Epub 2024 Jun 26 doi: 10.1016/j.clgc.2024.102141. PMID: 39107157
Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
Kato R, Obara W, Matsuura T, Kato Y, Iwasaki K, Fujioka T
Jpn J Clin Oncol 2014 May;44(5):479-85. Epub 2014 Mar 30 doi: 10.1093/jjco/hyu018. PMID: 24688083
Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma.
Sonpavde G, Hutson TE
Clin Genitourin Cancer 2008 Dec;6 Suppl 1:S29-36. doi: 10.3816/cgc.2008.s.005. PMID: 19891127

Recent clinical studies

Etiology

Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results.
Nathan P, Venugopal B, Ali J, Allison J, Ceruso M, Charnley N, Griffiths R, Michael A, Moore K, Perrot V, Prendergast Á, Sharma A, Szabados B, Larkin J
Clin Genitourin Cancer 2024 Oct;22(5):102141. Epub 2024 Jun 26 doi: 10.1016/j.clgc.2024.102141. PMID: 39107157
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM
Ann Oncol 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676. PMID: 28049139Free PMC Article
Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma.
Massacesi C, Burattini L, Marcucci F, Bonsignori M
J Interferon Cytokine Res 2005 Mar;25(3):165-8. doi: 10.1089/jir.2005.25.165. PMID: 15767790
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML
J Clin Oncol 2004 Mar 1;22(5):909-18. doi: 10.1200/JCO.2004.08.185. PMID: 14990647
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ
Cancer 2001 Sep 15;92(6):1567-76. doi: 10.1002/1097-0142(20010915)92:6<1567::aid-cncr1483>3.0.co;2-l. PMID: 11745236

Diagnosis

Real-world Treatment Sequencing and Outcomes With Cabozantinib After First-line Immune Checkpoint Inhibitor-based Combination Therapy For Patients With Advanced Renal Cell Carcinoma: CARINA Study Results.
Nathan P, Venugopal B, Ali J, Allison J, Ceruso M, Charnley N, Griffiths R, Michael A, Moore K, Perrot V, Prendergast Á, Sharma A, Szabados B, Larkin J
Clin Genitourin Cancer 2024 Oct;22(5):102141. Epub 2024 Jun 26 doi: 10.1016/j.clgc.2024.102141. PMID: 39107157
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E
Ann Oncol 2002 Aug;13(8):1259-63. doi: 10.1093/annonc/mdf195. PMID: 12181250

Therapy

Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
Passi I, Billowria K, Kumar B, Chawla PA
Anticancer Agents Med Chem 2023;23(5):562-570. doi: 10.2174/1871520622666220617103126. PMID: 35718972
Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
Viray H, McDermott DF, Einstein DJ
Expert Rev Anticancer Ther 2022 Jul;22(7):695-702. Epub 2022 Jun 17 doi: 10.1080/14737140.2022.2088515. PMID: 35698870
Emerging therapeutics in refractory renal cell carcinoma.
Koshkin VS, Rini BI
Expert Opin Pharmacother 2016 Jun;17(9):1225-32. Epub 2016 May 23 doi: 10.1080/14656566.2016.1182987. PMID: 27112171
Second-line therapy for refractory renal-cell carcinoma.
Zustovich F, Lombardi G, Nicoletto O, Pastorelli D
Crit Rev Oncol Hematol 2012 Jul;83(1):112-22. Epub 2011 Sep 22 doi: 10.1016/j.critrevonc.2011.08.008. PMID: 21944739
Allogeneic stem cell transplantation for renal cell carcinoma.
Bregni M, Herr W, Blaise D; Solid Tumor Working Party of EBMT
Expert Rev Anticancer Ther 2011 Jun;11(6):901-11. doi: 10.1586/era.11.12. PMID: 21707287

Prognosis

Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
Passi I, Billowria K, Kumar B, Chawla PA
Anticancer Agents Med Chem 2023;23(5):562-570. doi: 10.2174/1871520622666220617103126. PMID: 35718972
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Chang E, Weinstock C, Zhang L, Fiero MH, Zhao M, Zahalka E, Ricks TK, Fourie Zirkelbach J, Qiu J, Yu J, Chen XH, Bhatnagar V, Goldberg KB, Tang S, Kluetz PG, Pazdur R, Ibrahim A, Beaver JA, Amiri-Kordestani L
Clin Cancer Res 2022 Feb 1;28(3):441-445. Epub 2021 Aug 20 doi: 10.1158/1078-0432.CCR-21-2334. PMID: 34417198Free PMC Article
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM
Ann Oncol 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676. PMID: 28049139Free PMC Article
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML
J Clin Oncol 2004 Mar 1;22(5):909-18. doi: 10.1200/JCO.2004.08.185. PMID: 14990647
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E
Ann Oncol 2002 Aug;13(8):1259-63. doi: 10.1093/annonc/mdf195. PMID: 12181250

Clinical prediction guides

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.
Massard C, Soria JC, Krauss J, Gordon M, Lockhart AC, Rasmussen E, Upreti VV, Patel S, Ngarmchamnanrith G, Henary H
Cancer Chemother Pharmacol 2019 Jun;83(6):1057-1063. Epub 2019 Mar 26 doi: 10.1007/s00280-019-03796-4. PMID: 30915497
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM
Ann Oncol 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676. PMID: 28049139Free PMC Article
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, Liu G, Eickhoff JC, McNeel DG, Malkovsky M
Cancer Immunol Immunother 2011 Oct;60(10):1447-60. Epub 2011 Jun 7 doi: 10.1007/s00262-011-1049-8. PMID: 21647691Free PMC Article
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E
Ann Oncol 2002 Aug;13(8):1259-63. doi: 10.1093/annonc/mdf195. PMID: 12181250
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ
Cancer 2001 Sep 15;92(6):1567-76. doi: 10.1002/1097-0142(20010915)92:6<1567::aid-cncr1483>3.0.co;2-l. PMID: 11745236

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...